Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Travere Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$46.74

-2.87 (-5.91%)

C 53Pipeline Score Fair Value Pharma · Commercial
Market Cap
4.13 B
EPS
-0.50
P/E Ratio
-
Value Trade
79.45 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    127.20 M

  • R&D Expenses

    57.09 M

  • Operating CF

    -40.37 M

  • Total Assets

    555.19 M

  • Total Liabilities

    456.46 M

  • Equity

    98.73 M

  • D/E Ratio

    12,345

2.16 %
Week
13.66 %
1 Month
50.71 %
3 Month
28.04 %
6 Month
141.21 %
5 Year
-92.41 %
All Time
Cash Data
Stable

  • Cash Position

    208.95 M

  • Monthly Burn

    13.46 M

  • Runway

    14.3 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 4, 2026
Overview
Volume
1.63 M
52 Week Range
13.88 - 48.61
% held by Insiders
2.84 %
% held by Institutions
110.18 %
Enterprise Value
4.19 B
Total Shares
92.23 M
Short %
15.62 %
Float Shares
90.39 M
Company Description
HQ: 3611 VALLEY CENTRE DR, SAN DIE...
Employees:497
https://www.travere.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C53
Pipeline Score
$1.2B
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.0x
rNPV / MCap
Top 77%
Small Cap
(rank 209 of 905)
Percentile Rank
Travere Therapeutics, Inc. carries a moderate pipeline score (53/100), with $1.9B risk-adjusted pipeline value, led by sparsentan in Immunoglobulin A Nephropathy (Phase 3), across $50B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
sparsentan
Small molecule		Immunoglobulin A NephropathyPhase 3NCT0376285055% $1.7B ACTIVE NOT_RECRUITING 478 SLOW A (80) Jul 1, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
FILSPARI (sparsentan)
IgA nephropathy (IgAN),focal segmental glomerulosclerosis (FSGS)
Phase 3
2025-08-28
FILSPARI (sparsentan)
IgA nephropathy (IgAN),focal segmental glomerulosclerosis (FSGS)
Phase 3
2025-08-28
FILSPARI (sparsentan)
IgA nephropathy (IgAN),focal segmental glomerulosclerosis (FSGS)
Phase 3
2025-08-28
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TVTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TVTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TVTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-09-18 0.00 0 - - - - - -
2026-09-18 0.00 0 - - - - - -
2026-09-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Travere Therapeutics, Inc. (TVTX) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TVTX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Metabolic Disorders #3 of 30 PHASE 3 Pegtibatinase
AZN SNY RARE
$21.15B 0.95 CONTENDER
IgA Nephropathy #3 of 8 PHASE 3 sparsentan + irbesartan + Dapagliflozin
NVS VERA BIIB
$46.82B 0.89 CONTENDER
Focal Segmental Glomerulosclerosis #5 of 6 PHASE 2 Sparsentan
APLS SNY NVS
$3.31B 0.88 CONTENDER
Vasculitis #6 of 16 PHASE 2 Sparsentan
AZN GSK ABBV
$2.5B 0.88 FOLLOWER
Rare Genetic Disorders #36 of 61 PHASE 2 Sparsentan
BMRN ASND NVS
—0.88 FOLLOWER